Whether left ventricular mass (LVM) should be normalized to different indexes in relation to body size is still debated. We sought to evaluate the prevalence of left ventricular hypertrophy (LVH) defined by different indexation criteria in a cohort of hypertensive subjects categorized according to body mass index (BMI). A total of 2213 essential hypertensive subjects included in the Evaluation of Target Organ Damage in Hypertension (ETODH) were divided in three groups according to BMI thresholds (o25, 25-29.9 and X30 kg m À2 ). All patients underwent extensive investigations including quantitative echocardiography. LVH was defined as an LVM index equal to or higher than (1) . A total of 845 patients (38.2%) had normal BMI, 954 patients (43.1%) were overweight and 414 (18.7%) were obese. Prevalence rates of LVH in the three groups were 25.1, 31.6, 41.2% by indexation to BSA and 29.9, 50.5, 71.8% by indexation to height 2.7 , respectively. LVM indexed to BSA markedly underestimates LVH prevalence in obese as well as overweight hypertensive patients. To avoid a systematic misclassification of cardiovascular risk, LVM should be routinely indexed to height 2.7 in overweight and obese patients representing a large percentage of the hypertensive population.
Whether left ventricular mass (LVM) should be normalized to different indexes in relation to body size is still debated. We sought to evaluate the prevalence of left ventricular hypertrophy (LVH) defined by different indexation criteria in a cohort of hypertensive subjects categorized according to body mass index (BMI). A total of 2213 essential hypertensive subjects included in the Evaluation of Target Organ Damage in Hypertension (ETODH) were divided in three groups according to BMI thresholds (o25, 25-29.9 and X30 kg m À2 ). All patients underwent extensive investigations including quantitative echocardiography. LVH was defined as an LVM index equal to or higher than (1) 125 g m À2 in men and 110 g m À2 in women, (2) 51 g m À2.7 in men and 47 g m À2.7 in women. Overall, 687 out of 2213 patients (31.0%) were found to have LVH when LVM was indexed to body surface area (BSA) and 1030 (46.5%) when indexed to height 2. 7 
Introduction
Left ventricular hypertrophy (LVH), as assessed by electrocardiography (EKG) or echocardiography, is a strong independent predictor of cardiovascular (CV) events. [1] [2] [3] [4] Detection of LVH by routine EKG or echocardiography is currently recommended by several guidelines to more effectively stratify CV risk and improve clinical decisions in hypertensive individuals.
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Obesity, a major unhealthy phenotype that is dramatically increasing in affluent countries, has been shown to be associated with LVH both in normotensive and hypertensive individuals. 8, 9 Several pathophysiological mechanisms have been advocated to explain the link between obesity and LVH in arterial hypertension: (1) increased intravascular volume; (2) exaggerated activation of the sympathetic and renin-angiotensin system; (3) abnormal production of myocardial growth substances from the adipose tissue; (4) metabolic alterations, often accompanying obesity, that contribute to the abnormal loading conditions by increasing large arteries stiffness. 10, 11 Despite a tight association between obesity and LVH, detection of this marker of subclinical cardiac damage may be hampered by several factors such as reduced sensitivity of EKG indexes or poor quality of echocardiographic examinations in obese subjects; moreover, a consensus on the criteria for left ventricular mass (LVM) indexing to body size parameters in this setting is still lacking. 12, 13 Two indexation criteria of LVM are widely used in routine practice and clinical studies: (1) indexation to body surface area (BSA), which has been documented to detect hypertension-related LVH and (2) indexation to height 2.7 , which is proposed to be similarly sensitive in detecting obesity-related and -unrelated LVH. Thus, in the present study we sought to investigate the sensitivity of the two methods in identifying increased LVM in different body mass index (BMI) categories in a population of lean, overweight and obese sustained hypertensive subjects.
Methods
The ETODH (Evaluation of Target Organ Damage in Hypertension) study is an ongoing observational registry of hypertension-related organ damage and concomitant CV risk factors in subjects with uncomplicated essential hypertension aimed at estimating total CV risk according to the international 5, 14 and European hypertension guidelines. 7, 15 Our analysis was performed on a population of men and women referred to the outpatient hypertension clinic of the Ospedale Maggiore Policlinico (Milan). High blood pressure (BP) was defined as a systolic BP (SBP) X140 mm Hg and/or diastolic BP (DBP) X90 mm Hg in untreated subjects. Treated hypertensive subjects were included regardless of BP values. Obesity was identified by the 1998 National Institutes of Health classification as BMI X30 kg m À2 . 16 Main exclusion criteria were a history or evidence of congestive heart failure, atrial fibrillation, previous stroke, significant cardiac valve disease (regurgitation 41 þ at Doppler examination, stenosis of any degree or presence of prosthesis), previous myocardial infarction or coronary bypass, secondary causes of hypertension and neoplastic disease. As described elsewhere, 17 after an informed written consent had been obtained, all patients underwent the following procedures within a 1-to 4-week interval: medical history and physical examination, clinic BP measurement, blood and urine sampling, standard 12-lead electrocardiogram, 24-h urine collection for microalbuminuria, non-mydriatic retinography, and cardiac, renal and carotid ultrasonography. The study protocol was approved by the ethics committee of one of the institutions involved.
The ETODH registry started in January 1999 and by the end of September 2006 had enrolled 3786 subjects with untreated (n ¼ 1270) or treated essential hypertension (n ¼ 2516).
For the present analysis we selected 2213 sustained hypertensive subjects (on antihypertensive treatment for at least previous 6 months) having a complete echocardiographic report, and categorized them in three BMI groups: lean (o25 kg m À2 ), overweight (25-29.9 kg m À2 ) and obese (X30 kg m À2 ).
Blood pressure measurement Clinic BP was measured at two different visits in the outpatient clinic using a mercury sphygmomanometer and taking the first and fifth phases of Koroktoff sounds to identify SBP and DBP, respectively. Measurements started after the subjects had rested for 5 min in the sitting position. Three measurements were taken at 1-min interval, and the average was used to define clinic SBP and DBP.
Echocardiography
Echocardiography was performed according to standardized procedures, as reported elsewhere. 17 All echocardiographic procedures were performed during 1999-2006 by two experienced persons (CC and SM) unaware of the clinical characteristics of the subjects examined. LVM was estimated from enddiastolic left ventricular internal diameter (LVIDd), interventricular septum and posterior wall thickness (PWT) according to Devereux's formula 18 and normalized to BSA and height 2.7 to obtain LVM index (LVMI). Relative wall thickness (RWT) was calculated as (2 Â PWT)/LVIDd.
Left ventricular hypertrophy was defined as LVMI equal to or higher than (1) 125 g m À2 in men and 110 g m À2 in women, 7 and (2) 51 g m À2.7 in men and 47 g m À2.7 in women. 19 Patterns of left ventricular geometry were defined according to Ganau et al.: 20 LV concentric remodelling, when a normal LVMI was combined with RWT X0.45; eccentric LVH, when increased LVMI was associated with RWT o0.45; and concentric LVH, when increased LVMI occurred with RWT X0.45. LV filling was assessed by mitral flow with standard pulsed Doppler technique. The following parameters were considered: early diastolic peak flow velocity (E), late diastolic peak flow velocity (A) and their ratio (E/A).
In a 10% sample of patients, randomly chosen, variability of LVMI measurement was evaluated: intra-observer and inter-observer coefficients of variation were 7.4 and 8.6% respectively.
Statistical analysis
Statistical analysis was performed by the SAS system (version 6.12; SAS Institute Inc., Cary, NC, USA). Values were expressed as means ± s.d. or as percentages. Continuous variables were compared by analysis of variance, using the Student's t-test for dual comparison. Analysis of categorical data was carried out with the w 2 -test or Fischer's exact test when appropriate. The strength of correlation between variables was tested by linear correlation analysis and multiple regression analysis. The limit of statistical significance was set at Po0.05.
Results
Of the 2213 hypertensive subjects examined, 1122 were men (50.7%). Mean age was 55.7 ± 10.7 (range 17-90) years. Mean clinic SBP and DBP were 147±19 and 91±10 mm Hg, respectively; BP values were X140/90 mm Hg in 79.1% of the study sample, the prevalence of metabolic syndrome (MS) was 42.5%, according to the amended National Cholesterol Education Program's Adult Treatment Panel III guidelines, 21 21 .5% of the subjects were smokers and 6.2% had type II diabetes mellitus, according to revised American Diabetes Association criteria (fasting serum glucose level X6.99 mmol l À1 , and/ or by current medical therapy with an oral hypoglycaemic agent and/or insulin). 42% of the patients were on monotherapy, 34% on two drugs, 18% on three drugs and 6% on four or more drugs in association. On the whole, considering both monotherapy and combination therapy, angiotensin II converting enzyme inhibitors/angiotensin II receptor blockers (63%), diuretics (46%) and calcium antagonists (37%) were the drugs most frequently prescribed.
As for body weight, 38.2% of the subjects were lean (group I: BMI o25 kg m À2 ), 43.1% overweight (group II: BMI 25-29.9 kg m À2 ) and 18.7% obese (group III: BMI X30 kg m À2 ). Clinical and demographic characteristics of these groups are reported in Table 1 . Average clinic SBP/ DBP, prevalence of men, MS, type II diabetes, fasting blood glucose, triglycerides, uric acid concentrations, urinary albumin excretion tended to be higher in obese and overweight than in lean hypertensive subjects; the opposite trend was observed for highdensity lipoprotein (HDL) cholesterol, clinic BP control (that is, o140/90 mm Hg) and prevalence of monotherapy. The differences were in most instances statistically significant.
Echocardiographic parameters are shown in Table 2 . As expected, LVIDd, LVIDs, absolute wall thickness, RWT, left atrium and aortic root diameter, absolute LVM and LVM indexed to BSA or height 2.7 showed a progressive increase across the groups, whereas the E/A value showed the opposite trend. Similar results were obtained in separate genderbased analyses (data not shown).
Prevalence of LVH
Overall, 687 out of 2213 patients (31.0%) were found to have LVH when LVM was indexed to BSA and 1030 (46.5%) when indexed to height 2.7 . Indexation by BSA determined a slight, not significant higher prevalence of LVH in men (32.8%) than in woman (29.2%), whereas indexation to height 2. 7 showed an opposite, non-significant trend (47.4% in women and 45.6% in men). A marked step-wise increase in LVH prevalence occurred from normal to overweight and obese hypertensive subjects by normalization to height 2.7 , whereas a less pronounced increase, reaching the statistical significance in obese hypertensives, was found by indexation to BSA (Figure 1 ). Lastly, no significant differences in the prevalence of LVH as defined by both criteria were observed in lean hypertensive individuals. A gender-related difference was observed when LVM was indexed to height 2.7 , in terms of a higher prevalence of LVH in overweight and obese women than men.
As for LV geometric patterns, eccentric LVH was prevalent over the concentric one regardless , whereas LV concentric remodelling was higher (15.2 vs 10.3%, by indexation to BSA). Moreover, the ratio between concentric/eccentric LVH did not significantly change across the groups after normalization to height 2.7 in the whole study population (from 0.53 in lean to 0.54 in obese), as well as in men (from 0.61 to 0.62) and in women (from 0.49 to 0.51). Similar findings were found by indexation to BSA.
Correlation analyses
In the whole population LVM indexed both to BSA and to height 2.7 showed significant and positive 
Discussion
The present study demonstrates that among sustained hypertensive subjects seen in a specialist centre definition of LVH according to genderspecific values indexed to BSA (that is, 125/ 110 g m À2 ) as compared to those indexed to height 2.7 (that is, 51/47 g m À2.7 ) may underestimate the prevalence of this marker of CV risk in obese as well as overweight individuals. In the whole population, LVH normalized to height to allometric power of 2.7 was 1.7-fold more prevalent in obese and 1.6-fold in overweight hypertensive individuals compared to the BSA indexation; these data indicate that LVM should be indexed to height not only in frank obese but also in overweight hypertensive subjects to improve CV risk stratification. Several aspects of our findings deserve to be commented.
First, it has been widely documented that the echocardiographic prevalence of LVH in hypertension is influenced by numerous demographic and clinical variables, such as age, race, gender, duration/severity of hypertension, concomitant risk factors, effective BP control and probably type of antihypertensive treatment, as obviously by the arbitrary thresholds and indexation criteria for LVH definition. In particular, it has been shown that indexation to height 2.7 provides the highest prevalence of LVH, to some extent independently from the cut-off settled, since this normalization identifies both obesity-and BP-related LVH. 22 In the VITAE Study (Ventriculo Izquierdo Tension Arterial Espana) including 946 essential hypertensives (53.3% women, 45% obese) from primary care centres, LVH prevalence ranged from 59.2% by indexing to BSA (that is, LVMI X111/102 g m À2 ) to 70.7% by indexing to height (that is, LVMI X50/ 47 g m À2.7 ). 23 In the Gubbio Population Study, a clinical survey performed in a small Italian town, the prevalence of LVH among 250 hypertensive patients was nearly twofold higher (43.6 vs 24.0%) when LVM was indexed to height (that is, LVMI 49.2/46.7 g m À2.7 ) compared to BSA indexation (that is, 116/104 g m À2 ). 24 Although these and other studies 13, 25 have shown that indexation of LVM to height raised to its allometric power yields the highest prevalence of LVH, no data are provided about the classification of subjects according to BMI categories, as performed in the present report.
A second notable aspect of our study refers to the relationship between types of LVH and body size. In our entire population, eccentric LVH was more frequent (approximately twofold higher) than the concentric one, regardless of the indexation method used. More importantly, eccentric/concentric ratio did not change across the BMI categories and when this ratio was taken into account in a gender-based analysis no substantial differences were found. This evidence shows that eccentric LVH was the prevalent LV geometric pattern in our essential hypertensives independently from the gender and BMI.
Third, although in our series obesity was present in a lower percentage (19%) than in previous studies reporting a two/threefold higher prevalence of this phenotype, 13, 23 we were able to show a large difference in LVH prevalence in the whole population as well as in the largest subgroup of overweight subjects by using the two indexation methods. The clinical relevance of this observation is that LVH should be identified by adjusting LVM to height not only in obese but also in overweight hypertensive individuals.
A final comment is deserved about some general aspects concerning (1) the prognostic value of LVH identified by LVM indexed to height; (2) the use of such normalization for clinical research purposes, particularly in LVH regression trials; (3) the implementation in clinical practice of LVH criteria based on indexation of mass to height 2.7 . Prospective studies comparing several indexation criteria in different populations indicated that the relative risk of mortality and morbidity is substantially similar among the diagnostic approaches tested. 19, [26] [27] [28] Of note, in line with previous reports, a recent study performed in American Indians with a high prevalence of obesity showed that population risk attributable to LVH is substantially higher when LVM is indexed to height 2.7 .
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In a review by our group examining 39 trials on LVH regression published in the past 12 years and including 9162 hypertensive subjects of both genders in 78 active treatment and 6 placebo arms, definition of LVH based on LVM indexed to height or height 2.7 was provided by only three studies. 29 In a region-based survey aimed at investigating the accuracy of echocardiographic LV determination in hypertensive patients in clinical practice, we found that LVMI was provided by only 24% of the echocardiographic reports examined; in almost all cases (96.2%) LVM was normalized to BSA and only in the remaining 3.8% to height 2.7 . 30 Overall, these findings support the view that indexation of LVM to height is rarely adopted in clinical research and current practice.
Limitation of the study
First, our data refer to a Caucasian population of hypertensive patients referred to a specialist centre; therefore, the present results may not apply to samples of different races or to the general hypertensive population seen in primary care. Second, the present study does not provide evidence on which is the best method for normalizing LVM, but confirms and extends previous information by showing that a significantly greater prevalence of LVH is identified by using gender-specific criteria indexed to height 2.7 (in line with cut-offs recommended by the Lang's inter-society report) 31 instead of those indexed to BSA suggested by the 2007 ESH/ESC; 7 off course, the use of non-gender-specific and/or different diagnostic partition values may have yielded different results in the entire population as well as in gender-based analyses (Table 3) . However, even with the most sensitive criteria indexed to BSA (that is, 4115/95 g m À2 ) 31 LVH remained undetected in a large fraction (approximately 20%) of obese hypertensive individuals.
Conclusion
Our study in a large cohort of sustained hypertensives indicates that identification of LVH by LVM normalized to BSA rather than to height 2.7 markedly underestimates the prevalence of this high-risk phenotype not only in obese, but also in overweight subjects. Since the prognostic value of LVH indexed to height has been widely documented, this indexation should be routinely adopted for the identification and treatment of this subclinical cardiac damage in overweight/obese subjects. Tables 1 and 2 .
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